亿帆医药：获得氢溴酸依他佐辛注射液药品注册证书

Core Viewpoint - Yifan Pharmaceutical (002019) has received approval for its drug, Hydrobromide Etizolam Injection, from the National Medical Products Administration, marking a significant milestone in its product development and market entry [1] Group 1: Product Approval and Market Entry - The company's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for Hydrobromide Etizolam Injection on April 8, 2025 [1] - The drug is indicated for pain relief, particularly for cancer pain and postoperative pain [1] - Yifan Pharmaceutical submitted the drug marketing application in June 2023 and received acceptance in July 2023 [1] Group 2: Market Position and Financials - As of the report date, the company is the first in China to pass the consistency evaluation for generic drugs [1] - The domestic sales revenue for 2023 reached 128 million yuan [1] - The company invested approximately 10.02 million yuan in research and development [1]